Skeletal alkaline phosphatase: a marker for individual follow-up in patients with advanced prostatic cancer.
Skeletal alkaline phosphatase (sAP) is a tumor marker indicating osseous metastases, e.g. of prostate cancer. Sera of healthy men and patients with benign prostatic hyperplasia (BPH), localized and advanced prostatic cancer (PCa) were analyzed with Tandem-R-Ostase and prostate-specific antigen (PSA). No significant differences were found in sAP levels between healthy men and patients with BPH and localized PCa, but there was a significant difference with the group of patients with advanced PCa. In some cases, the individual follow-up was better and earlier with sAP compared to PSA. It is possible to discriminate between localized and advanced PCa with sAP. The individual follow-up shows in 30% of patients with advanced PCa an earlier increase in sAP, compared to PSA, during progression of disease.
Wechsel
H W
HW
Department of Urology, Eberhard Karls University, Tübingen, Germany.
Petri
E
E
Bichler
K H
KH
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000556:secondary*; D004796:Clinical Enzyme Tests; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*; D013997:Time Factors
D014408:Biomarkers, Tumor; D000469:Alkaline Phosphatase; D017430:Prostate-Specific Antigen